Australian Regulators Target Caffeine Combo Stimulants

Law360, New York (October 15, 2013, 7:51 PM EDT) -- Australian drug regulators are targeting for review herbal stimulants — and similar products containing both caffeine and oxedrine that are used as recreational stimulants — that may pose serious health risks, including stroke and heart attack, the country's health department said Tuesday.

Australia’s Therapeutic Goods Administration, the country’s authority overseeing therapeutic products, said Tuesday that it is conducting a full review of products that contain a combination of caffeine and oxedrine — a chemical that affects the body’s adrenaline production — including energy supplements, appetite suppressants...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.